patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: Yesterday's News, June 14, 2012

Just a brief interview. Nothing new, but at least you can see and hear a face from the company.

Pluristem Director Dr. Liat Flaishon Interviewed on CorporateProfile.com
12:42p ET June 14, 2012 (Market Wire) Corporate Profile, LLC announced today that Pluristem Therapeutics, Inc. (NASDAQ: PSTI) (TASE: PLTR) Director Dr. Liat Flaishon, was interviewed on www.CorporateProfile.com

The video can be viewed at: www.corporateprofile.com and http://www.corporateprofile.com/?p=3250

Share
New Message
Please login to post a reply